Loading
A phase 2 trial of ADU-S100 in Head and neck squamous cell carcinoma, run by Chinook Therapeutics, Inc. (formerly Aduro), recorded as terminated on the registry.
Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer is a phase 2 interventional study registered as NCT03937141 by Chinook Therapeutics, Inc. (formerly Aduro), with 16 participants recorded, started 2019-08-26 and due to reach its primary completion in 2021-05-10. Interventions recorded: ADU-S100. Conditions recorded: Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer.
Linked to the drug ADU-S100 because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/